About Albireo Pharma (NASDAQ:ALBO)
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. The company's clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALBO
CUSIPN/A
Phone857-254-5555
Debt
Debt-to-Equity RatioN/A
Current Ratio6.95%
Quick Ratio6.95%
Price-To-Earnings
Trailing P/E Ratio-10.49
Forward P/E Ratio43.14
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.01 per share
Price / Book5.53
Profitability
EPS (Most Recent Fiscal Year)($3.15)
Net Income$-24,410,000.00
Net MarginsN/A
Return on Equity-40.90%
Return on Assets-36.04%
Miscellaneous
Employees22
Outstanding Shares11,900,000
Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions
What is Albireo Pharma's stock symbol?
Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."
How were Albireo Pharma's earnings last quarter?
Albireo Pharma, Inc. (NASDAQ:ALBO) released its quarterly earnings results on Thursday, March, 15th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.23. View Albireo Pharma's Earnings History.
What price target have analysts set for ALBO?
4 brokerages have issued 1 year target prices for Albireo Pharma's stock. Their predictions range from $50.00 to $92.00. On average, they expect Albireo Pharma's share price to reach $68.3333 in the next year. View Analyst Ratings for Albireo Pharma.
What are Wall Street analysts saying about Albireo Pharma stock?
Here are some recent quotes from research analysts about Albireo Pharma stock:
- 1. According to Zacks Investment Research, "Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. " (3/30/2018)
- 2. Needham & Company LLC analysts commented, "Albireo mgmt hosted a 4Q17 conference call today to provide a corporate update. Company remains on track for initiation of Phase 3 testing of IBAT inhibitor A4250 in Progressive Familiar Intrahepatic Cholestasis (PFIC) in the near future. As a reminder, Albireo presented encouraging data from a Phase 2 trial in rare pediatric cholestatic liver diseases, including PFIC, in 2017. Mgmt guided for Phase 3 top-line results by YE19, w/ regulatory submissions shortly thereafter. Albireo also plans to evaluate elobixibat in Non-Alcoholic Steatohepatitis (NASH), although not until early 2019. Evaluation of A4250 in other rare pediatric cholestatic liver diseases and testing of A3384 in Bile Acid Malabsorption is still planned, but deprioritized in order to focus on A4250 in PFIC. We believe stock is undervalued and reiterate BUY." (3/15/2018)
- 3. Wedbush analysts commented, "Zynerba updated its plans to focus development on rare and near-rare neurological and psychiatric disorders." (1/3/2018)
- 4. Cowen Inc analysts commented, "Albireo reported 3Q earnings today and provided a brief summary of recent progress." (11/17/2017)
Who are some of Albireo Pharma's key competitors?
Some companies that are related to Albireo Pharma include Deciphera Pharmaceuticals (DCPH), OptiNose (OPTN), Vanda Pharmaceuticals (VNDA), GlycoMimetics (GLYC), Karyopharm Therapeutics (KPTI), CymaBay Therapeutics (CBAY), AMAG Pharmaceuticals (AMAG), Omeros (OMER), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals (ANIP), NuCana (NCNA), Endocyte (ECYT), Adamas Pharmaceuticals (ADMS), Rocket Pharmaceuticals (RCKT), Rhythm Pharmaceuticals (RYTM), Lannett (LCI), Geron (GERN) and Ziopharm Oncology (ZIOP).
Who are Albireo Pharma's key executives?
Albireo Pharma's management team includes the folowing people:
- Mr. Ronald H. W. Cooper, Chief Exec. Officer, Pres and Director (Age 55)
- Dr. Jan P. Mattsson Ph.D., Chief Operating Officer (Age 54)
- Mr. Peter A. Zorn, Chief Corp. Officer, Gen. Counsel & Sec. (Age 48)
- Dr. Per-Goran Gillberg Ph.D., Co-Founder and VP of Devel.
- Mr. Thomas A. Shea MBA, Chief Financial Officer and Treasurer (Age 58)
Has Albireo Pharma been receiving favorable news coverage?
Media coverage about ALBO stock has been trending somewhat positive recently, according to Accern. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Albireo Pharma earned a daily sentiment score of 0.17 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.37 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Albireo Pharma?
Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Albireo Pharma's stock price today?
One share of ALBO stock can currently be purchased for approximately $33.22.
How big of a company is Albireo Pharma?
Albireo Pharma has a market capitalization of $392.01 million. The biopharmaceutical company earns $-24,410,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. Albireo Pharma employs 22 workers across the globe.
How can I contact Albireo Pharma?
Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]
MarketBeat Community Rating for Albireo Pharma (ALBO)
MarketBeat's community ratings are surveys of what our community members think about Albireo Pharma and other stocks. Vote "Outperform" if you believe ALBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALBO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Albireo Pharma (NASDAQ:ALBO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Albireo Pharma in the last 12 months. Their average twelve-month price target is $68.3333, suggesting that the stock has a possible upside of 105.70%. The high price target for ALBO is $92.00 and the low price target for ALBO is $50.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $68.3333 | $66.6667 | $61.6667 | $46.50 |
| Price Target Upside: | 105.70% upside | 87.48% upside | 86.87% upside | 99.57% upside |
Albireo Pharma (NASDAQ:ALBO) Consensus Price Target History
Albireo Pharma (NASDAQ:ALBO) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Albireo Pharma (NASDAQ:ALBO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Albireo Pharma (NASDAQ ALBO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 22.30%
Institutional Ownership Percentage: 26.86%
Albireo Pharma (NASDAQ ALBO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/30/2018 | Phase4 Partners Ltd | Major Shareholder | Sell | 100,000 | $34.44 | $3,444,000.00 | |  |
| 1/25/2018 | Life Sciences Maste Perceptive | Major Shareholder | Buy | 275,000 | $33.00 | $9,075,000.00 | | |
| 12/1/2017 | Plc Astrazeneca | Major Shareholder | Sell | 500,000 | $21.40 | $10,700,000.00 | | |
| 12/20/2013 | Brian Jg Pereira | Director | Sell | 4,734 | $2.26 | $10,698.84 | | |
(Data available from 1/1/2013 forward)
Albireo Pharma (NASDAQ ALBO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | BidaskClub Lowers Albireo Pharma (ALBO) to Sell
www.americanbankingnews.com - April 19 at 11:10 AM |
 | Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting
finance.yahoo.com - April 19 at 9:33 AM |
| Albireo Pharma (ALBO) Receives New Coverage from Analysts at Needham & Company LLC
www.americanbankingnews.com - April 17 at 6:29 PM |
 | Albireo Pharma (ALBO) Annoucnes Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver ...
www.streetinsider.com - April 16 at 9:27 AM |
 | Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at The ...
globenewswire.com - April 16 at 9:27 AM |
| Albireo Pharma (ALBO) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - April 8 at 2:04 PM |
| Albireo Pharma, Inc. (ALBO) Expected to Announce Quarterly Sales of $55.00 Million
www.americanbankingnews.com - April 4 at 2:30 AM |
| $3.81 Earnings Per Share Expected for Albireo Pharma, Inc. (ALBO) This Quarter
www.americanbankingnews.com - April 2 at 5:16 PM |
| Albireo Pharma (ALBO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 30 at 4:32 PM |
| Albireo Pharma, Inc. to Post Q1 2018 Earnings of $3.57 Per Share, Wedbush Forecasts (ALBO)
www.americanbankingnews.com - March 30 at 6:50 AM |
 | Albireo Pharma (ALBO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:23 PM |
| Albireo Pharma, Inc. (ALBO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 29 at 3:24 AM |
| Albireo Pharma (ALBO) to Present Clinical Data on A4250 at The International Liver Congress
www.streetinsider.com - March 28 at 4:21 PM |
| Albireo Pharma (ALBO) Lowered to Hold at BidaskClub
www.americanbankingnews.com - March 28 at 11:55 AM |
| Albireo Pharma's (ALBO) "Outperform" Rating Reaffirmed at Wedbush
www.americanbankingnews.com - March 28 at 11:11 AM |
| Albireo to Present Clinical Data on A4250 at The International Liver Congress™ 2018
finance.yahoo.com - March 28 at 9:48 AM |
| Albireo Pharma (ALBO) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - March 26 at 9:57 AM |
| Albireo Pharma (ALBO) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM |
| Albireo Pharma (ALBO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 24 at 1:54 PM |
| Albireo to Present at 17th Annual Needham & Company Healthcare ... - GlobeNewswire (press release)
globenewswire.com - March 21 at 4:20 PM |
 | Albireo to Present at 17th Annual Needham & Company Healthcare Conference - Nasdaq
www.nasdaq.com - March 21 at 10:44 AM |
| Albireo to Present at 17th Annual Needham & Company Healthcare Conference
finance.yahoo.com - March 21 at 10:44 AM |
| Albireo Pharma (ALBO) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 19 at 5:02 PM |
| Q1 2018 EPS Estimates for Albireo Pharma, Inc. (ALBO) Raised by William Blair
www.americanbankingnews.com - March 19 at 1:56 AM |
| Albireo Reports Fourth Quarter and Year-End 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 17 at 9:48 AM |
 | BRIEF-Albireo Reports Fourth Quarter And Year-End 2017 Financial Results
www.reuters.com - March 15 at 4:51 PM |
| Albireo Pharma (ALBO) Now Covered by Analysts at Needham & Company LLC
www.americanbankingnews.com - March 15 at 4:20 PM |
| Albireo Pharma (ALBO) Releases Earnings Results, Beats Expectations By $0.23 EPS
www.americanbankingnews.com - March 15 at 1:38 PM |
| Albireo Pharma, Inc. to Host Earnings Call
finance.yahoo.com - March 15 at 9:28 AM |
| Albireo Reports Fourth Quarter and Year-End 2017 Financial Results
finance.yahoo.com - March 15 at 9:28 AM |
| Albireo Pharma (ALBO) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 9 at 11:48 PM |
 | Constipation Therapeutics - Pipeline Analysis 2017 Featuring Nordic Life Science Pipeline Inc., Enterin Inc., and Yuhan Corporation Ltd
www.bizjournals.com - March 8 at 9:55 AM |
| Albireo to Present at 38th Annual Cowen and Company Health Care Conference
finance.yahoo.com - March 6 at 9:25 AM |
| Albireo Pharma, Inc. (ALBO) Shares Bought by Sectoral Asset Management Inc
www.americanbankingnews.com - March 5 at 4:06 PM |
| Albireo Pharma, Inc. (ALBO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 4 at 3:30 AM |
| Albireo Pharma, Inc. (ALBO) Expected to Post Earnings of -$0.78 Per Share
www.americanbankingnews.com - February 27 at 1:30 PM |
| BidaskClub Downgrades Albireo Pharma (ALBO) to Hold
www.americanbankingnews.com - February 25 at 6:35 PM |
| Albireo Pharma (ALBO) and Alexza Pharmaceuticals (ALXA) Critical Review
www.americanbankingnews.com - February 20 at 9:08 PM |
| Head-To-Head Contrast: Albireo Pharma (ALBO) versus Alexza Pharmaceuticals (ALXA)
www.americanbankingnews.com - February 17 at 7:32 PM |
| Analyzing Alexza Pharmaceuticals (ALXA) and Albireo Pharma (ALBO)
www.americanbankingnews.com - February 17 at 1:16 AM |
| Reviewing Albireo Pharma (ALBO) and Alexza Pharmaceuticals (ALXA)
www.americanbankingnews.com - February 15 at 11:12 PM |
| Critical Comparison: Alexza Pharmaceuticals (ALXA) and Albireo Pharma (ALBO)
www.americanbankingnews.com - February 8 at 11:20 AM |
| Needham & Company LLC Raises Albireo Pharma (ALBO) Price Target to $50.00
www.americanbankingnews.com - February 2 at 2:25 PM |
| Albireo Pharma, Inc. (ALBO) Major Shareholder Sells $3,444,000.00 in Stock
www.americanbankingnews.com - February 1 at 6:10 PM |
| Albireo Announces Closing of $74.8 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - January 29 at 4:28 PM |
| Albireo Pharma, Inc. (ALBO) Major Shareholder Life Sciences Maste Perceptive Buys 275,000 Shares
www.americanbankingnews.com - January 25 at 9:12 PM |
| Albireo Prices $65.0 Million Public Offering of Common Stock
finance.yahoo.com - January 25 at 9:05 AM |
| Zacks: Analysts Anticipate Albireo Pharma, Inc. (ALBO) to Post -$0.78 EPS
www.americanbankingnews.com - January 24 at 11:10 PM |
| Albireo Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 24 at 4:47 PM |
| Albireo Pharma (ALBO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 24 at 4:06 PM |
Albireo Pharma (NASDAQ:ALBO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Albireo Pharma (NASDAQ:ALBO) Income Statement, Balance Sheet and Cash Flow Statement
Albireo Pharma (NASDAQ ALBO) Stock Chart for Thursday, April, 19, 2018
Loading chart…
